Intracellular allosteric antagonism of the CCR9 receptor
暂无分享,去创建一个
Ali Jazayeri | Jonathan S. Mason | Francesca Deflorian | Miles Congreve | Mathieu Rappas | M. Congreve | J. Mason | F. Deflorian | A. Doré | J. Errey | F. Marshall | R. Cooke | A. Jazayeri | K. Bennett | C. Oswald | J. Christopher | Andrew S. Doré | Fiona H. Marshall | James Kean | John A. Christopher | James C. Errey | Robert M. Cooke | Christine Oswald | Kirstie Bennett | M. Rappas | J. Kean | A. S. Doré
[1] J. Changeux,et al. Allosteric modulation as a unifying mechanism for receptor function and regulation , 2017, Diabetes, obesity & metabolism.
[2] Johannes Söding,et al. The MPI bioinformatics Toolkit as an integrative platform for advanced protein sequence and structure analysis , 2016, Nucleic Acids Res..
[3] S. P. Andrews,et al. Extra-helical binding site of a glucagon receptor antagonist , 2016, Nature.
[4] S. Keshav,et al. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease , 2015, Clinical and experimental gastroenterology.
[5] L. Kremer,et al. Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges , 2015, Front. Immunol..
[6] R. Solari,et al. "Chemokine receptors as therapeutic targets: Why aren't there more drugs?". , 2015, European journal of pharmacology.
[7] Garth J. Williams,et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser , 2014, Nature.
[8] Benjamin G Tehan,et al. Unifying family A GPCR theories of activation. , 2014, Pharmacology & therapeutics.
[9] Hualiang Jiang,et al. Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.
[10] David T. Jones,et al. Membrane protein orientation and refinement using a knowledge-based statistical potential , 2013, BMC Bioinformatics.
[11] Ali Jazayeri,et al. Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.
[12] K. Diederichs,et al. Better models by discarding data? , 2013, Acta crystallographica. Section D, Biological crystallography.
[13] Philip R. Evans,et al. How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.
[14] P. Zwart,et al. Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.
[15] T. Wilkin,et al. CCR5 antagonism in HIV infection: current concepts and future opportunities. , 2012, Annual review of medicine.
[16] Xavier Deupi,et al. Structural insights into agonist-induced activation of G-protein-coupled receptors. , 2011, Current opinion in structural biology.
[17] R. Tal-Singer,et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. , 2011, British journal of clinical pharmacology.
[18] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[19] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[20] J. Pease. Targeting chemokine receptors in allergic disease. , 2011, The Biochemical journal.
[21] Nathan Robertson,et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.
[22] Pallavi Sachdev,et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells , 2010, Proceedings of the National Academy of Sciences.
[23] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[24] Yu Wang,et al. Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.
[25] S. Charlton,et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor , 2010, British journal of pharmacology.
[26] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[27] Wolfgang Kabsch,et al. Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.
[28] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[29] R. Leurs,et al. Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.
[30] D. Nicholls,et al. Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 , 2008, Molecular Pharmacology.
[31] K. Wreggett,et al. An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5 , 2008, Molecular Pharmacology.
[32] Yoko Shibata,et al. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.
[33] M. Billah,et al. Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist , 2007, Journal of Pharmacology and Experimental Therapeutics.
[34] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[35] Eric Gouaux,et al. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. , 2006, Structure.
[36] M. Thelen,et al. Dancing to the tune of chemokines , 2001, Nature Immunology.
[37] R. Horuk,et al. Chemokine Receptor Antagonists , 2000, Medicinal research reviews.
[38] M. Klein,et al. Constant pressure molecular dynamics algorithms , 1994 .
[39] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[40] V. Cherezov,et al. Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.